29 results about "Downregulated gene" patented technology

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human FXI mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating FXI gene expression and treating or preventing a disease or disorder associated with aberrant or increased expression or activity of FXI or a disease or disorder where FXI plays a role.

The invention discloses an application of ZmAPX1 (ZmAPX1) in regulating and controlling the resistance of corn to a maize chlorotic mottle virus (MCMV), and belongs to the technical field of plant genetic engineering. Through instantaneous silencing of ZmAPX1 and use of a ZmAPX1 mutant, it is proved that down-regulation of expression of the ZmAPX1 gene can reduce the immunity of plants to MCMV, and through construction of an over-expression ZmAPX1 strain, it is proved that ZmAPX1 can enhance the immunity of plants to MCMV. Therefore, the ZmAPX1 is proved to have the function of positively regulating the MCMV resistance of the corn.

The application discloses application of a circFOXO3 gene expression inhibitor in preparation of a medicine for preventing and / or treating periodontitis, and belongs to the technical field of medicines.The siRNA of the circFOXO3 is adopted to down-regulate the expression of the circFOXO3 gene, so that the expression amount of ITGB6 is up-regulated, the activation of TGF-beta 1 is promoted, and then the occurrence and development of periodontitis are inhibited.The siRNA of the cholesterol-modified circFOXO3 can increase the stability and in-vivo metabolic time of the siRNA.

The application discloses an intervention strategy for targeting CACNA2D2 protein and application thereof, and belongs to the technical field of medicine and biotechnology.The application discloses for the first time that abnormal high expression of CACNA2D2 is related to poor prognosis of neuroblastoma, especially malignant progression, and provides that CACNA2D2 gene is used as a drug target to prepare a drug for treating neuroblastoma, and further provides application of CACNA2D2 siRNA in preparation of a drug for treating neuroblastoma.After down-regulation of CACNA2D2 gene expression, cell proliferation and clone formation ability of neuroblastoma cells are significantly inhibited.Therefore, the application provides a new direction for development of a drug for treating neuroblastoma, and provides a possibility for preparing a new drug for treating neuroblastoma, improving curative effect of patients, improving prognosis and survival.

The application relates to the technical field of biological information, and discloses a plant stress relief key gene tracing method and system based on transcriptome data. The method comprises the following steps: performing high-throughput transcriptome sequencing on plant leaves of four treatment groups, obtaining clean transcriptome data through quality filtering; obtaining a whole genome expression matrix through transcript assembly and redundancy removal processing, performing intersection screening on stress induction up-regulated genes and relief agent silencing down-regulated genes, and obtaining a stress induction-relief agent silencing candidate gene set; constructing a stress induction co-expression topology network by taking the candidate gene set as a silencing annotation basis, calculating a weighted neighbor silencing rate to obtain a topology feature matrix; training a selective silencing probability prediction model through a logistic regression model by taking the topology feature matrix and the candidate gene set, and performing channel enrichment calculation by taking the silencing probability as a weight to screen and obtain a core tracing gene set. The application improves the biological credibility of key gene tracing results and the cross-scene adaptability of the method.

The invention discloses an application of a substance taking Angpt18 as a target in preparation of a medicine for treating and delaying senescence, and the key regulation effect of an Angpt18 gene in the occurrence and progression process of normal senescence and senescence-related diseases is found for the first time through systematic and in-depth research; further experiments prove that by inhibiting or down-regulating the expression of the Angpt18 gene, the senescence process can be obviously delayed, and the expressions such as hypomnesia and behavioral ability decline in the senescence process can be effectively improved. Therefore, the Angpt18 gene can be used as an important intervention target for senescence and related diseases thereof, can be used for developing drugs with senescence delaying or treatment effects, can also be used as a biomarker for evaluating the senescence degree and diagnosing and prognosing the related diseases of senescence, and has wide application prospects and clinical transformation values.

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human FXI mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating FXI gene expression and treating or preventing a disease or disorder associated with aberrant or increased expression or activity of FXI or a disease or disorder where FXI plays a role.

This invention discloses a fish-derived bioactive peptide with dual functions of enhancing saltiness and inhibiting adipocyte differentiation, and its applications, belonging to the field of biotechnology. The bioactive peptide is a γ-glutamylarginine peptide with the general formula γ-[Glu]n-Arg, where n is an integer from 1 to 4. This invention efficiently prepared a series of γ-[Glu]n-Arg peptides through a targeted enzymatic synthesis method, further elucidating the dual effects of this bioactive peptide at the molecular mechanism level. The bioactive peptide can effectively enhance saltiness perception by binding to the saltiness receptor TMC4, and inhibit adipocyte differentiation and reduce lipid accumulation through multiple targets by downregulating PPAR-γ, C / EBPα, and FAS genes, and upregulating AMPK and HSL genes. This invention provides a reliable scientific basis and technical support for developing innovative food ingredients with both flavoring and health functions.

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human APP mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating APP gene expression and treating or preventing a disease or disorder associated with aberrant or increased expression or activity of APP or a disease or disorder where APP plays a role.

The invention discloses a related protein GmPP2C338 for regulating and controlling the salt tolerance of a plant as well as a related biological material and application of the related protein GmPP2C338. And the protein sequence of the soybean protein GmPP2C338 is as shown in a sequence 2. The technical problem to be solved by the invention is how to improve the salt tolerance of plants. The invention specifically discloses a protein, and an encoding gene of the protein is applied to the following applications: A1) application of a product for improving the salt tolerance of plants; a2) plant breeding and / or preparation of plant breeding products. The salt tolerance of a plant of which the expression of the GmPP2C338 protein coding gene is knocked out / reduced is obviously higher than that of a control plant. The substance for inhibiting or reducing or down-regulating the expression of the GmPP2C338 gene can be used for improving the salt tolerance of plants and can be used for plant breeding.

The invention discloses application of MBD3 as an intervention target in preparation of a neuroblastoma treatment medicine, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, a substance for reducing the expression level of the MBD3 gene or reducing the protein level of the MBD3 is applied to the development of a medicine for treating the neuroblastoma, and it is proved that interference on the expression of the MBD3 gene can induce the G0 / G1 phase cell cycle arrest of neuroblastoma cells and promote cell apoptosis, so that the in-vivo and in-vitro proliferation activity of the neuroblastoma cells is effectively inhibited; the small-molecule drug enbopiravidone can down-regulate the MBD3 protein level and significantly inhibit the growth of neuroblastoma cells. According to the invention, MBD3 is taken as a new target spot for treating neuroblastoma, a new direction is provided for overcoming the limitation of the existing therapy, a scientific basis is provided for developing a novel neuroblastoma treatment strategy based on MBD3 inhibition, and the application has important significance for improving the living quality and survival prognosis of high-risk children.

The invention discloses a RanGAP1 gene and an application of the RanGAP1 gene in regulating and controlling the reproduction of female diaphorina citri. The nucleotide sequence of the DcRanGAP1 gene is shown as SEQ ID NO.9. After female diaphorina citri subjected to eclosion for 8 days down-regulates expression of the DcRanGAP1 gene, the early stage of egg laying is remarkably prolonged, the egg laying period is remarkably shortened, the egg laying amount is remarkably reduced, development of an ovary is remarkably inhibited, and the titer of the Huanglongbing in the ovary is remarkably reduced, so that the purpose of preventing and treating the diaphorina citri is achieved, and the diaphorina citri can be used for preventing and treating the diaphorina citri. A new thought is provided for preventing and treating the Huanglongbing.

The application discloses a kind of drug for treating heart toxicity caused by VEGFR inhibitor with CXCL12 gene or protein as target point, belongs to medical technology field.The drug reverses heart toxicity caused by VEGFR inhibitor by down-regulating the expression of CXCL12 gene or the accumulation of CXCL12 protein in heart.Specifically, the application provides shRNA, neutralizing antibody or small molecule drug targeting CXCL12 as drug for reversing heart toxicity caused by VEGFR inhibitor.The application provides new intervention target and effective strategy for intervention of heart dysfunction caused by VEGFR inhibitor such as lefratinib, and provides feasible medication scheme for clinic.

The invention discloses an application of a polypeptide of a targeted NTRK3 gene in preparation of a medicine for inhibiting the growth of PAX3-FOXO1 fusion positive rhabdomyosarcoma. The invention provides the application of the NTRK3 protein as a drug target to preparation of the drug for resisting malignant proliferation of the PAX3-FOXO1 fusion positive rhabdomyosarcoma for the first time. Furthermore, by down-regulating the expression of the NTRK3 gene, the clone formation capability of the PAX3-FOXO1 fused positive rhabdomyosarcoma cells is remarkably inhibited. Therefore, the invention not only discloses the application of the NTRK3 gene, but also provides a new therapeutic target for the PAX3-FOXO1 fusion positive rhabdomyosarcoma. The invention provides possibility for preparing a novel medicine for treating the PAX3-FOXO1 fusion positive rhabdomyosarcoma and improving the prognosis condition of a patient.

The invention relates to the field of biological medicine, in particular to application of a reagent for inhibiting or down-regulating ABLIM1 gene expression in preparation of a medicine for preventing ionizing radiation injury. The invention discloses a new application of the reagent for inhibiting or down-regulating the expression of the ABLIM1 gene for the first time, and the reagent can effectively improve the radiation resistance of normal cells. Experimental results show that the sgRNA for inhibiting the expression of the ABLIM1 gene can promote the clone formation ability of normal cells, promote the activity of the normal cells and inhibit the DNA damage of irradiation to the normal cells, so that the radiation damage protection effect is improved.

Compositions and methods for modifying genomic DNA sequences are provided. The methods produce double-stranded breaks (DSBs) at pre-determined target sites in a genomic DNA sequence, resulting in mutation, insertion, and / or deletion of DNA sequences at the target site(s) in a genome. Compositions comprise DNA constructs comprising nucleotide sequences that encode a Cms1 protein operably linked to a promoter that is operable in the cells of interest. The DNA constructs can be used to direct the modification of genomic DNA at pre-determined genomic loci. Methods to use these DNA constructs to modify genomic DNA sequences are described herein. Additionally, compositions and methods for modulating the expression of genes are provided. Compositions comprise DNA constructs comprising a promoter that is operable in the cells of interest operably linked to nucleotide sequences that encode a mutated Cms1 protein with an abolished ability to produce DSBs, optionally linked to a domain that regulates transcriptional activity. The methods can be used to up-or down-regulate the expression of genes at predetermined genomic loci.

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human APP mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating APP gene expression and treating or preventing a disease or disorder associated with aberrant or increased expression or activity of APP or a disease or disorder where APP plays a role.

Disclosed is a substance which down-regulates the activity of a MAST gene, or the activity of a transcription or translation product of a MAST gene, for use in the prevent and / or treatment of an inflammatory skin condition in a mammalian subject.

The invention discloses an application of a transcription factor EC gene in preparation of drugs for treating leukemia, and particularly relates to an application of interfering RNA (Ribonucleic Acid) of a targeted transcription factor EC (TFEC) gene in preparation of drugs for treating acute myelogenous leukemia. The invention provides application of the TFEC gene as a drug target to preparation of the drug for treating the AML for the first time, and further provides application of the TFEC interfering RNA to preparation of the drug for treating the AML. After the expression of the TFEC gene is down-regulated, the cell proliferation and clone formation ability of AML cells are obviously inhibited, and the drug sensitivity is obviously improved. Therefore, the invention provides a new direction for the development of AML treatment medicines, and provides possibilities for preparing new AML treatment medicines, improving the curative effect of patients and improving prognosis and survival.

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human PLG mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating PLG gene expression and treating or preventing a disease or disorder associated with aberrant or increased expression or activity of PLG or a disease or disorder where PLG plays a role.

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human MSTN mRNA, delivery systems, kits, and compositions comprising the same, and methods of using the same for inhibiting or downregulating MSTN gene expression and treating or preventing a disease or disorder associated with aberrant or increased expression or activity of MSTN or a disease or disorder where MSTN plays a role.

The invention relates to a regulating element for regulating the content of resistant starch in rice and application thereof in the technical field of plant genetic engineering. The regulatory element provided by the invention contains a nucleotide sequence as shown in SEQ ID NO. 1 and / or SEQ ID NO. 2. A CRISPR / Cas9 gene editing technology is used for carrying out fixed-point editing on the regulatory element in rice, and the expression level of the SBEIIb gene can be reduced after the regulatory element is mutated, so that the content of resistant starch in the rice is improved, and a gene resource and a technical thought are provided for improving the quality of the rice.

The invention discloses an application of a reagent for inhibiting or down-regulating an RIPK1 gene in preparation of a tumor radiotherapy sensitizing drug. The reagent for inhibiting or down-regulating the RIPK1 gene refers to a reagent for inhibiting or down-regulating the expression of the RIPK1 gene. The invention provides a reagent for inhibiting or down-regulating RIPK1 gene expression, namely siRNA of a targeted RIPK1 gene, and a clone formation experiment, an apoptosis experiment, a comet electrophoresis experiment and an immunofluorescence experiment prove that the siRNA of the targeted RIPK1 gene can remarkably inhibit the survival rate of colorectal cancer cells after irradiation, increase the damage degree of DNA after irradiation and enable the cells to be more sensitive to radiation. The siRNA of the targeted RIPK1 gene provided by the invention can effectively improve the radiosensitivity of tumor cells in the radiotherapy process, and especially can effectively improve the radiosensitivity of colorectal cancer.

This invention discloses RanGAP1 Genes and their application in regulating the reproduction of female citrus psyllids. DcRanGAP1 The nucleotide sequence of the gene is shown in SEQ ID NO.9. The female citrus psyllid, eight days after emergence, showed a downregulation. DcRanGAP1 After gene expression, the pre-oviposition period is significantly prolonged, the oviposition period is significantly shortened, the number of eggs laid is significantly reduced, and ovarian development is significantly inhibited and the Huanglongbing titer in the ovary is significantly reduced, thereby achieving the goal of controlling citrus psyllids and providing a new approach to the prevention and control of Huanglongbing.

The invention discloses a medicine for treating hepatotoxicity of bosutinib by taking a CAMK2G gene or protein as a target spot, and belongs to the technical field of medicines. According to the medicine, the hepatotoxicity of bosutinib is relieved by down-regulating the expression of the CAMK2G gene or restoring the phosphorylation of the CAMK2G protein. The invention reveals that the CAMK2G gene is a key gene of liver injury and abnormal glucose metabolism caused by bosutinib, and provides a new prevention and treatment target for intervening hepatotoxicity caused by bosutinib. According to the invention, the CAMK2G phosphorylation activator is utilized to recover CAMK2G phosphorylation to relieve liver injury and abnormal glucose metabolism, a new direction is provided for finding an intervention strategy for causing hepatotoxicity by drugs, and the current situation that few intervention drugs can be used clinically and the mechanism is single is solved to a certain extent.

The invention provides an mRNA vaccine for synergistically knocking down PCSK9 gene expression, and belongs to the field of biological medicine. The mRNA vaccine comprises siRNA of a targeted silence PCSK9 gene, mRNA encoding ovalbumin (OVA), and lipid nanoparticles containing a fluorinated modified pegylated lipid. According to the siRNA, the level of an MHC I complex is improved by down-regulating the expression quantity of a PCSK9 gene; the mRNA is used for improving the expression level of antigens in cells; the delivery efficiency of mRNA is improved by the lipid nanoparticles, and a foundation is laid for the curative effect of the vaccine. The mRNA vaccine is proved to be capable of remarkably improving the antigen presentation efficiency of tumor cells, strongly inducing an organism to generate immune response, remarkably inhibiting tumor growth and prolonging the service life of tumor-bearing mice; and it is proved that the combination of the siRNA and the mRNA has a synergistic interaction effect.

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human MSTN mRNA, delivery systems, kits, and compositions comprising the same, and methods of using the same for inhibiting or downregulating MSTN gene expression and treating or preventing a disease or disorder associated with aberrant or increased expression or activity of MSTN or a disease or disorder where MSTN plays a role.

Compositions and methods for treating traumatic brain injury (TBI) are presented. Novel dendriplexes are formed from poly(amidoamine) (PAMAM) dendrimers complexed with shRNA encoding DNA plasmids encapsulating shRNA encoding chemokine ligand 20 (CCL20) gene, chemokine receptor 6 (CCR6) gene, or a combination thereof. The dendriplexes are dually administered, both intranasally and intravenously, prior to administration of stem cells, such as human mesenchymal stem cells (hMSCs) for the treatment of traumatic brain injury (TBI). Administration of the dendriplexes prior to stem cell administration resulted in a decrease in neurodegeneration, neuroinflammation, microgliosis and astrogliosis. In addition, a synergistic increase in brain derived trophic factor (BDNF) was shown by administration of the combination of dendriplex and stem cell administration.

The application belongs to the technical field of biological medicine, and particularly relates to PRMT2 interfering lentivirus and application thereof. The application designs the interfering lentivirus by taking PRMT2 as a target, and studies the role and mechanism of the interfering lentivirus in triple-negative breast cancer. Experiments show that the interfering lentivirus PRMT2-KD1 and PRMT2-KD2 can down-regulate PRMT2 gene expression, inhibit cell migration, invasion and aerobic glycolysis; the PRMT2 high-expression plasmid combined with a glycolysis inhibitor verifies that PRMT2 affects cell migration and invasion by regulating aerobic glycolysis; animal experiments show that the PRMT2 interfering lentivirus can inhibit lung metastasis of mouse triple-negative breast cancer. The above results suggest that PRMT2 can be used as a drug target for the treatment of triple-negative breast cancer metastasis.